1. Home
  2. BELFB vs LQDA Comparison

BELFB vs LQDA Comparison

Compare BELFB & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bel Fuse Inc. Class B

BELFB

Bel Fuse Inc. Class B

HOLD

Current Price

$254.51

Market Cap

3.5B

Sector

N/A

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$61.59

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BELFB
LQDA
Founded
1949
2004
Country
United States
United States
Employees
4964
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.4B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BELFB
LQDA
Price
$254.51
$61.59
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
11
Target Price
$174.25
$41.00
AVG Volume (30 Days)
250.0K
1.4M
Earning Date
04-29-2026
05-08-2026
Dividend Yield
0.11%
N/A
EPS Growth
N/A
51.81
EPS
N/A
0.52
Revenue
N/A
$158,320,000.00
Revenue This Year
$9.74
$278.87
Revenue Next Year
$6.34
$57.13
P/E Ratio
$42.80
$115.77
Revenue Growth
N/A
1031.18
52 Week Low
$70.87
$11.85
52 Week High
$308.27
$60.55

Technical Indicators

Market Signals
Indicator
BELFB
LQDA
Relative Strength Index (RSI) 46.66 81.95
Support Level $241.14 $30.48
Resistance Level $308.27 N/A
Average True Range (ATR) 14.22 3.68
MACD -6.15 1.68
Stochastic Oscillator 14.01 98.21

Price Performance

Historical Comparison
BELFB
LQDA

About BELFB Bel Fuse Inc. Class B

Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: